Evidence map›Paper›PMID 30226551›Full record

ArticleOncology reports2018

Interaction of hematopoietic CD34+ CD45+ stem cells and cancer cells stimulated by TGF‑β1 in a model of glioblastoma in vitro.

Elena Milkina, Arina Ponomarenko, Maria Korneyko, Irina Lyakhova, Yulia Zayats, Sergey Zaitsev, Polina Mischenko, Marina Eliseikina, Yuri Khotimchenko, Valeryi Shevchenko and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Kinins in Glioblastoma Microenvironment.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Elena MilkinaSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Arina PonomarenkoSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Maria KorneykoSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Irina LyakhovaSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Yulia ZayatsSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Sergey ZaitsevSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Polina MischenkoSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Marina EliseikinaNational Scientific Center of Marine Biology FEB RAS, Vladivostok 690041, Russia.
Yuri KhotimchenkoSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Valeryi ShevchenkoSchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Hari SharmaInternational Experimental CNS Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, University Hospital, Uppsala University, Uppsala, SE‑75185, Sweden.
Igor BryukhovetskiySchool of Biomedicine of The Far Eastern Federal University, Vladivostok 690091, Russia.
Far Eastern Federal University · RUFar Eastern Branch of the Russian Academy of Sciences · RUUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of modern treatment methods for malignant brain tumors are not sufficiently effective, with a median survival time varying between 9 and 14 months. Metastatic and invasive processes are the principal characteristics of malignant tumors. The most important pathogenic mechanism is epithelial‑mesenchymal transition (EMT), which causes epithelial cells to become more mobile, and capable of invading the surrounding tissues and migrating to distant organs. Transforming growth factor‑β1 (TGF‑β1) serves a key role in EMT‑inducing mechanisms. The current study presented the interaction between hematopoietic stem cells and glioblastoma cells stimulated by TGF‑β1 in vitro. The materials for the study were hematopoietic progenitor cell antigen CD34+ hematopoietic stem cells (HSCs) and U87 glioblastoma cells. Cell culture methods, automated monitoring of cell‑cell interactions, confocal laser microscopy, flow cytometry and electron microscopy were used. It was demonstrated that U87 cells have a complex communication system, including adhesive intercellular contacts, areas of interdigitation with dissolution of the cytoplasm, cell fusion, communication microtubes and microvesicles. TGF‑β1 affected glioblastoma cells by modifying the cell shape and intensifying their exocrine function. HSCs migrated to glioblastoma cells, interacted with them and exchanged fluorescent tags. Stimulation of cancer cells with TGF‑β1 weakened the ability of glioblastoma cells to attract HSCs and exchange a fluorescent tag. This process stimulated cancer cell proliferation, which is an indication of the ability of HSCs to 'switch' the proliferation and invasion processes in glioblastoma cells.

Indexed as

Antigens, CD34Cell Culture TechniquesCell DifferentiationCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFlow CytometryGene Expression Regulation, NeoplasticGlioblastomaHematopoietic Stem CellsHumansLeukocyte Common AntigensNeoplasm InvasivenessNeoplasm MetastasisTransforming Growth Factor beta1Antigens, CD34Leukocyte Common AntigensTransforming Growth Factor beta1

Identifiers

PMID30226551
PMCPMC6151884
OpenAlexW2888060626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.